Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)

According to data presented during the 2020 ASH Annual Meeting, a pooled analysis of four chronic lymphocytic leukemia clinical trials demonstrated that only 17% of patients receiving acalabrutinib monotherapy experienced cardiac toxicity of any grade at a median follow-up of 25.9 months, leading to treatment discontinuation in 0.9%.

202 ASH Annual Meeting